AGO-OVAR 2.29/ENGOT-ov34: atezolizumab vs placebo + bevacizumab w/ chemo recurrent ovarian cancer

Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy ...Подробнее

Is It Time to Change Upfront Chemotherapy for Ovarian Cancer?Подробнее

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovaria...Подробнее

GOG-0218: which patients with ovarian cancer experience highest benefit from 1L bevacizumab?Подробнее

Dr. Jason A. Konner on Bevacizumab in Advanced Ovarian CancerПодробнее

When to Add Bevacizumab for Recurrent Ovarian CancerПодробнее

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian CancerПодробнее

Bevacizumab’s Value in Recurrent Ovarian CancerПодробнее

Bevacizumab for Recurrent Ovarian CancerПодробнее

Ovarian cancer Phase III trial updates: IMagyn050 and ICON8Подробнее

Ovarian Cancer Subtypes May Predict Response to BevacizumabПодробнее

The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian C...Подробнее

Dr. Maurie Markman on the Phase III AURELIA Trial for Platinum-Resistant Ovarian CancerПодробнее

Rationalizing Use of Pembrolizumab/Bevacizumab in Recurrent Ovarian CancerПодробнее

Dr. Mirza on the Evolving Treatment Landscape in Recurrent Ovarian CancerПодробнее

Dr. Konner on Preferred Platinum Doublets in Recurrent Ovarian CancerПодробнее

AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancerПодробнее

Maintenance Therapy for Recurrent Advanced Ovarian CancerПодробнее

ASCO: Targeted Agent Slows Recurrent Ovarian CancerПодробнее